We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Track real-time Director Deals activity on the London Stock Exchange (LSE)
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bioventix Plc | LSE:BVXP | London | Ordinary Share | GB00B4QVDF07 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 100.00 | 3.85% | 2,700.00 | 1,989 | 16:35:02 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2,600.00 | 2,700.00 | 2,650.00 | 2,600.00 | 2,650.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 13.61M | 8.1M | 1.5497 | 17.10 | 135.85M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:02 | O | 1 | 2,700.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 28/4/2025 | 17:13 | UK RNS | BioVentix PLC Director Dealing |
| 11/4/2025 | 07:00 | UK RNS | BioVentix PLC Exercise of Options and Issue of Equity |
| 01/4/2025 | 13:00 | ALNC |  EARNINGS: Caledonia Mining profit multiplies; Portmeirion revenue down |
| 31/3/2025 | 07:00 | UK RNS | BioVentix PLC Interim Results |
| 24/12/2024 | 09:14 | UK RNS | BioVentix PLC Director Dealing |
| 06/12/2024 | 07:00 | UK RNS | BioVentix PLC Result of AGM |
| 04/12/2024 | 15:34 | UK RNS | BioVentix PLC Holding(s) in Company |
| 22/11/2024 | 15:56 | UK RNS | BioVentix PLC Director/PDMR Shareholding |
| 08/11/2024 | 07:57 | UK RNS | BioVentix PLC Notice of AGM |
| 31/10/2024 | 07:00 | UK RNS | BioVentix PLC Director/PDMR Shareholding |
Bioventix (BVXP) Share Charts1 Year Bioventix Chart |
|
1 Month Bioventix Chart |
Intraday Bioventix Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 18/6/2025 | 08:47 | Bioventix - Sheep Antibodies | 1,637 |
| 08/11/2016 | 13:07 | ShareSoc Supper in Brighton | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:35:02 | 2,700.00 | 1 | 27.00 | O |
| 15:35:02 | 2,700.00 | 10 | 270.00 | UT |
| 15:05:57 | 2,669.00 | 93 | 2,482.17 | O |
| 15:01:50 | 2,669.00 | 100 | 2,669.00 | O |
| 14:53:41 | 2,615.00 | 4 | 104.60 | O |
| Top Posts |
|---|
Posted at 23/6/2025 09:20 by Bioventix Daily Update Bioventix Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker BVXP. The last closing price for Bioventix was 2,600p.Bioventix currently has 5,224,860 shares in issue. The market capitalisation of Bioventix is £138,458,790. Bioventix has a price to earnings ratio (PE ratio) of 17.10. This morning BVXP shares opened at 2,650p |
Posted at 02/4/2025 21:14 by brucie5 Now on my watchlist for any fresh funds into the April's ISA. 5 year low, just below 50% of peak share price reached in early 24. It does seem to have a record of progressive dividends, and currently pays c. 6.5%.On the long term chart it looks to have broken down through the COVID low, suggesting 2000 as next support. Passes two good value screens on Stocko, including John Neff and Be Graham and scores 94 for quality with very high ROC, ROE and operating margin of 76%. If the dividend gets to 7%, I would see this as very attractive. Are there concerns here about US tariffs? |
Posted at 24/3/2025 16:16 by james188 I do not agree that BVXP management/the BoD are coasting. Those who were able to attend the AGM last December will have heard management quite enthused - particularly about the prospects for their growing Tau antibody portfolio (the last post also refers). BVXP typically underpromises and overdelivers. It has had a couple of muted years, but it remains a high quality offering. |
Posted at 24/3/2025 10:18 by multibagger It is an income generating stock which may suit some, but not a growth stock anymore IMHO. The slow share price drift downwards would make the dividend yields more attractive to whom that is important. A cash cow for now but for how long ?As a biotechnology company with a small niche, the writing is on the wall unless BVXP come up with some fresh products/adopt new technology and methods. The question is whether the founding team and BoD have an appetite for that, or would prefer to gently sail into the sunset ? As an investor set your expectation sails accordingly.....good luck ! |
Posted at 12/2/2025 14:50 by lozzer69 Lowest Share Price for 3 years |
Posted at 10/2/2025 20:29 by melody9999 LLama - I respect and value posts that are factually accurate and that offer insight. Less interested in opinion.When you say "The company cannot compete with large pharma" other less knowleadgeble readers might draw the conclusion that because of this BVXP does not have a future. Which is not the case. As you say, BVXP occupy the same sector as big pharma. But thats all. As I suspect we both know, BVXP provide antibodies that are used by large pharma and in that sense BVXP are suppliers to large pharma and not competitors. |
Posted at 10/2/2025 16:52 by melody9999 LLama - when you suggest BVXP is competing with big pharma, you show your ignorance of the company.Suggest you go research the company. Alternatively you may not wish too ... thats Ok too .... but in which case there is no basis on which you can offer advice to other investors. |
Posted at 29/10/2024 06:48 by multibagger Good morning all :)My post has landed badly - unfortunate. I understand the science and can see where tech in this area is heading and invest with 5-10 year timeframes at a minimum unless the story changes. Though antibodies will have their niche role they will diminish in importance, there is a potential Eastman Kodak v digital, video cassette v digital streaming moment here. Some may prefer not to see what is coming and what was a cash cow could stagnate or diminish - investing is about looking forwards. I am not here to try and persuade you to invest anywhere :) I have got into APTA fairly recently, so looking at their historical share price at 117p is immaterial to my investment decision. Good luck and we can take stock in about 3-5 years time as to the relative share prices of BVXP and APTA if the AIM market still exists and we are all around. I wish you well - investing is not a zero sum game but an infinite one. We make our choices and decide what to buy and when to exit. A note from a very successful, happy and cheerful dimwit :) For the record: Share prices on the day of the post, 28 Oct 2024 APTA: 0.225p BVXP : £ 32.50 |
Posted at 28/10/2024 09:32 by indiestu The price action this morning screams positive to me, lots of buyers coming in when the price was taken down first thing. Quite a pleasing reversal so far. This could have been a final wash out before the next big rally. I liked this section of the results. Revenues are peanuts at present but the growth could be significant. It must be very difficult to shake people out of their shares in Bioventix.'Our research into Tau antibodies and Alzheimer's diagnostics continues to progress and we are delighted that our early work has now translated into a modest revenue stream from antibodies now entering commercial manufacture. Our commercial policy is to supply initial evaluation samples of antibodies free of charge. If antibodies perform well on prototype assay systems at our IVD customers and additional supplies are ordered, these are charged at regular prices and such repeat sales have generated revenues during the year. These revenues are not only additive but also indicate that our antibodies could feature in future commercial assays. In addition to our conventional IVD customers, we have also supplied antibodies to specialist platform customers, for example Quanterix Corporation who specialise in assays for the research market. The research market is established earlier than more regulated tests for routine clinical use and it is pleasing that royalty revenues from such activities have already been established. Total Tau revenues for the year were above our expectation at £155k'. |
Posted at 25/10/2024 09:35 by sharesoc Join ShareSoc for the Growth Company Seminar/Webinar – 27th November 2024 (London)On 27th November, ShareSoc is hosting a Growth Company Seminar in London featuring presentations from: Bioventix (BVXP) – Peter Harrison, CEO Polar Capital Global Financials Trust plc (PCFT) – Tom Dorner, Fund Manager Altona Rare Earths (REE) – Dr. Cedric Simonet, CEO Wheaton Precious Metals (WPM) – Randy Smallwood, President & CEO Schedule: 5:00 pm start 25-minute presentations 15-minute Q&A after each presentation Networking over drinks and buffet Attend in-person or watch virtually. Register Here: |
Posted at 13/9/2024 13:51 by melody9999 Sharw 1583 re communication that has always been the case. But in the last few weeks I think the possible Budget changes to IHT AIM and CGT increases have caused the share price retrace.BVXP is perhaps the best example of a great AIM share that has a large proportion of long term holders. Sadly I think concerns about the Budget has caused some of them to reduce. I have a medium size holding, have not sold any .... and will be looking to add if we see continued weakness. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
